Piper Sandler Maintains Overweight on Cue Biopharma, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Cue Biopharma (NASDAQ:CUE) and raised the price target from $7 to $8.
November 06, 2023 | 3:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has maintained an Overweight rating on Cue Biopharma and raised the price target from $7 to $8, which could lead to a positive market reaction.
The raised price target by Piper Sandler indicates a positive outlook for Cue Biopharma. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100